Loading organizations...
MAOLAC is a technology company.
MAOLAC develops protein intelligence bio-actives, focusing on functional milk proteins to provide indication-specific health benefits. The company utilizes a proprietary AI precision system to discover and optimize these bio-actives, aiming to introduce proteins with a perfect fit for human biology. This approach extracts the natural power of milk components, delivering targeted support for various health needs, including immune system enhancement and overall wellness.
Founded in 2020 by Eli Lerner, Ariel Orbach, and Maya Ashkenazi, MAOLAC emerged from the insight that breast milk contains a unique blueprint for protection and nourishment. The founders recognized the potential to harness these complex functional proteins, traditionally vital for infants, and apply their benefits to adult health, translating nature's design into advanced nutritional solutions.
MAOLAC’s products target adults seeking enhanced immune function, improved sports nutrition, and support for healthy aging. The company envisions revolutionizing health by unlocking the full potential of human milk proteins. Their mission extends beyond supplementation, aiming to transform how beneficial nutrition is discovered and delivered, establishing a new paradigm for natural, biologically aligned wellness.
MAOLAC has raised $3.0M across 1 funding round.
MAOLAC has raised $3.0M in total across 1 funding round.
MAOLAC has raised $3.0M in total across 1 funding round.
MAOLAC's investors include OurCrowd, AME Cloud Ventures, Glilot Capital Partners, Hardware Club, Renegade Partners, Yair Tauman, Yaron Lemelbaum, Mediterranean Towers Ventures, NAOMI Investments, Strauss Group, The Food Tech Lab, Ventures Israel.
Maolac is an Israel-based startup founded in 2018 that develops bio-functional protein ingredients for the nutraceutical sector, mimicking human breast milk proteins for adult health applications.[1][2][4] The company uses proprietary AI platforms like Maoreka and Maolactin to analyze scientific data, identify optimal protein combinations from sources such as bovine colostrum, fungi, and plant side streams, and produce clinically tested blends addressing gut health, immunity, muscle strength, and more.[1][2][3][6] These ingredients target manufacturers of functional foods, beverages, supplements, and sports nutrition products, solving the challenge of delivering precise, bio-similar nutrition with high bioavailability in formats like gummies and bars.[1][4][6] Maolac has raised under $5 million in funding, achieved Self-Affirmed GRAS status in the US, and launched products like Maolac Super Colostrum, which provides benefits in just 140mg daily doses.[1][4][6]
Maolac was founded in 2018 in Yoqne'am Illit, Israel, by CEO Maya Ashkenazi Otmazgin (also listed as Maya Ashkenaz), an engineer with degrees in pharmaceutical and biomedical engineering, alongside board members Ariel Orbach and Eli Lerner.[2][4] Ashkenazi's journey stems from a childhood dream of scientific impact, evolving through her career in product innovation across industries; she left conservative paths to co-found Maolac with a supportive team.[2] The idea emerged from leveraging AI to decode proteins in human breast milk—the "gold standard" for nutrition—and source bio-similar ones from bovine colostrum for scalable adult use.[1][3][4] Early traction included building a unique protein library, recent funding for expansion, and pivots to broader sources like plant side streams, with US product launches and commercial deals anticipated.[1][4][5]
Maolac rides the convergence of AI-driven biotech and personalized nutrition, capitalizing on surging demand for functional foods amid rising chronic issues like gut dysbiosis and inflammation.[1][2][4] Timing aligns with post-pandemic health focus, US regulatory progress (GRAS status), and side-stream sustainability trends in food tech, enabling platform expansion beyond colostrum.[4] Market forces favor it: nutraceuticals growing via sports/infant nutrition, AI reducing R&D costs, and bio-similars bridging dairy/plant gaps.[1][6] Maolac influences the ecosystem by partnering with tech giants, supplying manufacturers, and pioneering "impact nutrition"—potentially reshaping supplement efficacy standards.[2]
Maolac is poised to scale US commercial deals in sports nutrition and functionals, while advancing pipelines for mental health and cognition via fungi/plant proteins.[4] Trends like AI precision med and sustainable biotech will accelerate growth, with its breast milk-inspired platform enabling bespoke blends amid regulatory tailwinds. Influence may evolve from niche innovator to ecosystem leader, powering next-gen supplements that outpace probiotics and generics—turning natural proteins into targeted human health superfoods, as its pioneering origins promised.[1][2][6]
MAOLAC has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in July 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2022 | $3.0M Seed | OurCrowd | AME Cloud Ventures, Glilot Capital Partners, Hardware Club, Renegade Partners, Yair Tauman, Yaron Lemelbaum, Mediterranean Towers Ventures, NAOMI Investments, Strauss Group, The Food Tech Lab, Ventures Israel |